- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07631442
Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)
8 juni 2026 uppdaterad av: Aparna Goel, Stanford University
Characterizing Fatigue, Sleep and Activity in Patients Living With Primary Biliary Cholangitis (PBC) Using Digital Health Technology
The purpose of this study is to explore the use of digital health technology for measuring symptoms and daily health in people with primary biliary cholangitis (PBC).
Biometric data captured with a wearable device will be compared to questionnaire responses (patient-reported outcomes, or PROs) and laboratory test results to test the hypothesis that changes in biometrics can be correlated to changes in disease activity.
Studieöversikt
Status
Anmälan via inbjudan
Betingelser
Detaljerad beskrivning
Patients enrolled are intended to start a second-line therapy (2L) for control of their PBC - the choice of therapy will be at the discretion of the treating hepatologist.
Once 2L therapy is initiated, the study will assess for correlations between changes in biochemistries (alkaline phosphatase, or ALP) with biometrics and PRO results.
Studietyp
Observationell
Inskrivning (Beräknad)
30
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
California
-
Redwood City, California, Förenta staterna, 94063
- Stanford University School of Medicine
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Testmetod
Icke-sannolikhetsprov
Studera befolkning
30 adult patients, diagnosed with PBC and with abnormal alkaline phosphatase (ALP)
Beskrivning
Inclusion Criteria:
PBC diagnosis based on meeting 2 of 3 criteria:
- Cholestatic liver biochemistry at disease outset (defined as elevation in the serum ALP level or GGT).
- Associated autoantibody (AMA or PBC-associated antinuclear antibody by immune fluorescence or anti-PDC, anti-Gp210, or anti-Sp100) at a titer of greater than or equal to 1:40.
- Diagnostic or compatible liver biopsy.
- Ability to provide informed consent
- Ability to complete digital questionnaires
- Elevated alkaline phosphatase
- Abbreviations:
alkaline phosphatase [ALP] gamma-glutamyl-transferase [GGT] antimitochondrial antibody [AMA] Primary Biliary Cholangitis [PBC] Plasmacytoid dendritic cells [PDC] glycoprotein 210 [Gp210] Scleroderma 100 [Sp100]
Exclusion Criteria:
- Uncontrolled chronic inflammatory condition that is likely to contribute to symptoms of poor fatigue and sleep and confound results.
- Active malignancy requiring treatment
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Patients with Primary Biliary Cholangitis (PBC) and an abnormal alkaline phosphatase (ALP)
Patients with an ALP >1.67x ULN will be preferentially enrolled, but all patients with an elevated ALP can be considered.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Sleep scores to assess sleep quality will be measured in PBC patients using a wearable device
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Sleep Score 0 - 100 where 0 is worst sleep experience and 100 is best sleep experience
|
7 months (1 month of screening and 6 months wearing device)
|
|
SpO2 (saturation of peripheral oxygen) levels to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
7 months (1 month of screening and 6 months wearing device)
|
|
|
Total time in bed, to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of hours per day spent in bed
|
7 months (1 month of screening and 6 months wearing device)
|
|
Total sleep, to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of hours per day spent asleep
|
7 months (1 month of screening and 6 months wearing device)
|
|
Sleep stage time series (REM), to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of hours per day spent in REM (Rapid Eye Movement) sleep
|
7 months (1 month of screening and 6 months wearing device)
|
|
Sleep stage time series (deep), to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of hours per day spent in deep sleep
|
7 months (1 month of screening and 6 months wearing device)
|
|
Sleep stage time series (light), to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of hours per day spent in light sleep
|
7 months (1 month of screening and 6 months wearing device)
|
|
Number of "get ups" during sleep, to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of times "getting up" during the night while trying to sleep
|
7 months (1 month of screening and 6 months wearing device)
|
|
Temperature deviation from baseline, to assess sleep quality
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
change in temperature over time during sleep cycle
|
7 months (1 month of screening and 6 months wearing device)
|
|
Heart rate
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
7 months (1 month of screening and 6 months wearing device)
|
|
|
Respiratory rate
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
7 months (1 month of screening and 6 months wearing device)
|
|
|
Calories burned during exercise to assess daily activity
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of calories burned during each exercise session
|
7 months (1 month of screening and 6 months wearing device)
|
|
Calories burned throughout the day to assess daily activity
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
total number of calories burned each day
|
7 months (1 month of screening and 6 months wearing device)
|
|
Distance traveled during exercise to assess daily activity
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
Number of miles traveled during each exercise session
|
7 months (1 month of screening and 6 months wearing device)
|
|
Number of steps to assess daily activity
Tidsram: 7 months (1 month of screening and 6 months wearing device)
|
total number of steps taken each day
|
7 months (1 month of screening and 6 months wearing device)
|
|
Change in PBC-40 fatigue domain score in patients with PBC
Tidsram: 7 months (1 month screening and 6 months wearing the device)
|
The PBC-40 fatigue domain allows a potential value range of 11 to 55 with higher values denoting worse fatigue.
A score of >33 identifies patients with moderate-severe fatigue and a mean change in this score by 5 points after 3 months has been used in other studies to denote clinically meaningful significance.
|
7 months (1 month screening and 6 months wearing the device)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in alkaline phosphatase (ALP) levels
Tidsram: Baseline and following 2L therapy (at doctor's discretion, within 7 month timeline)
|
ALP levels (where lower levels reflect better control of PBC disease) will be measured in patients both before and after a second-line therapy (2L) is started.
|
Baseline and following 2L therapy (at doctor's discretion, within 7 month timeline)
|
|
Changes in Daily Fatigue Impact Scale.
Tidsram: 7 months (1 month screening and 6 months wearing the device)
|
The Daily Fatigue Impact Scale measures how fatigue interferes with daily functioning.
Scores range from 0 to 32, with higher numbers indicating a greater severity of fatigue.
|
7 months (1 month screening and 6 months wearing the device)
|
|
Change in Epworth Sleepiness Scale (ESS) score
Tidsram: 7 months (1 month screening and 6 months wearing the device)
|
The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24.
A result from 11 to 24 indicates excessive (abnormal) daytime sleepiness.
|
7 months (1 month screening and 6 months wearing the device)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Aparna Goel, MD, Stanford University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 juli 2026
Primärt slutförande (Beräknad)
1 oktober 2027
Avslutad studie (Beräknad)
1 april 2028
Studieregistreringsdatum
Först inskickad
4 maj 2026
Först inskickad som uppfyllde QC-kriterierna
1 juni 2026
Första postat (Faktisk)
8 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
11 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
8 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Beteendesymtom
- Matsmältningssystemets sjukdomar
- Hudmanifestationer
- Gallvägssjukdomar
- Hudsjukdomar
- Gallgångssjukdomar
- Fibros
- Kolestas, intrahepatisk
- Kolestas
- Levercirros
- Patologiska tillstånd, tecken och symtom
- Beteende
- Hud- och bindvävssjukdomar
- Tecken och symtom
- Trötthet
- Leversjukdomar
- Levercirros, gallvägar
- Klåda
- Mental trötthet
Andra studie-ID-nummer
- 83091
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .